IP Library Granted Patent US 7,927,878
Granted Patent B2
US 7,927,878 · App. 11/628,168 · Granted Apr 19, 2011

Process for the determination of lipoproteins in body fluids

Assignee: LipoFIT Analytic GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,927,878
App. No.
11/628,168
Granted
Apr 19, 2011
Kind
B2
Abstract

The invention describes a process for the determination of the concentration distribution and size distribution of lipoprotein classes in body fluids, e.g. blood. For this purpose, NMR spectra of a sample to be analysed are measured by magnetic field gradient intensities and temperatures under different diffusion-weighted measuring conditions selected according to different pulse programs (e.g. PFG-STE, PFG-LED etc) and consequently in a differentiated manner according to the relaxation times. The different effects of these measuring conditions on the intensity/line form of the NMR signals of the individual lipoprotein classes are determined and permit the determination of a concentration distribution/size distribution of the individual lipoprotein classes.

Claims (59)

1. A process for the determination of lipoprotein classes in a body fluids sample, comprising

measuring the NMR spectra of the body fluid sample under different measuring conditions which are selected from the group consisting of different magnetic field gradients and varying temperatures and

determining characteristic reference parameters for each individual lipoprotein class based on the different effects of these measuring conditions on the intensity and line forms of the NMR spectra of the individual lipoprotein class and assigning a density distribution and/or size distribution to the individual lipoprotein classes on the basis of the characteristic reference parameters.

2. The process according to claim 1 , wherein

characteristic reference parameters of an NMR spectrum are determined beforehand for each lipoprotein class to be analysed; and the measured NMR spectra of the body fluid sample to be analysed are fitted using calculated NMR spectra which are obtained by varying and combining these characteristic reference parameters.

3. The process according to claim 2 , wherein

the characteristic reference parameters are selected from the group consisting of:

chemical shift, NMR signal intensity and NMR signal form as a function of magnetic field gradients.

4. The process according to claim 1 including the process steps of:

A) Determining an NMR reference data set for each lipoprotein class with the characteristic reference parameters and calculating the effects of the different measuring conditions on the signal intensity and/or line widths of each lipoprotein class as a function of its size distribution and/or density distribution on the basis of the reference parameters,

B) Calculating an NMR reference spectra based on the NMR reference data set;

C) Determining the NMR spectra of the body fluid sample under the different measuring conditions used in A),

D) Fitting the calculated NMR spectra to the spectra determined in C) by means of a weighting of the reference parameters of each lipoprotein class.

5. The process according to claim 4 , wherein

in process step A), the NMR reference data set for each lipoprotein class are recorded under the different measuring conditions and the calculated NMR spectra are fitted to the NMR reference spectra by way of a sum of frequency-shifted and intensity-weighted base functions, a mathematical function being obtained for the characteristic reference parameters of the reference spectra.

6. The process according to claim 4 , wherein

in process step A), the characteristic reference parameters of each lipoprotein class are calculated using mathematical models.

7. The process according to claim 4 , wherein

in process step D), calculated NMR spectra are fitted to NMR spectra of the body fluid sample, detected in C), by weighting the characteristic reference parameters on the basis of weighting factors, and

the density and/or size distribution of the individual lipoprotein classes in the body fluid sample is determined using the weighting factors determined.

8. The process according to claim 7 , wherein

in process step D) the concentrations of the individual lipoprotein classes are additionally obtained.

9. The process according to claim 4 , wherein

in process steps A) and C) 1D NMR spectra of reference samples and body fluid samples to be analysed are detected.

10. The process according to claim 4 , wherein

the concentrations of non-lipoprotein components in the body fluid sample are additionally determined.

11. The process according to claim 10 wherein

NMR reference data sets for each non-lipoprotein component with the characteristic reference parameters is determined in process step A), and

in process step D), the concentrations of the non-lipoprotein components are additionally determined.

12. The process according to claim 10 , wherein

the non-lipoprotein components are selected from the group consisting of organic molecules, alcohol, amino acids, peptides, nucleic acids, fatty acids, carbohydrates, pharmaceuticals and proteins.

13. The process according to claim 1 , wherein

the lipoprotein classes are selected from the group consisting of:

chylomicron-A, chylomicron-B, chylomicron-C, chylomicron remnants, VLDL-A, VLDL-B, VLDL-C, IDL, small dense LDL, LDL-A, LDL-B, LDL-C, HDL-2, HDL-3 and Lp(a).

14. The process according to claim 1 , wherein

the magnetic field gradients are varied exclusively as measuring conditions and the different effects of the various magnetic field gradients on the intensity of the NMR signals of the individual lipoprotein classes are determined.

15. The process according to claim 14 , wherein

at least four 1D NMR spectra of the body fluid sample are recorded with different magnetic field gradients in each case.

16. The process according to claim 1 , wherein

the density distribution and/or size distribution and the concentration of other in-homogeneous particles other than lipoproteins in the body fluid sample are determined by measuring the NMR spectra of the body fluid sample under the different measuring conditions as used to determine the density and/or size distributions of the lipoprotein classes.

17. The process according to claim 1 , wherein

variations in the T 1 and T 2 relaxation times observed in the NMR spectra of the body fluid sample under the different measuring conditions are used for assigning a density distribution and/or size distribution to the individual lipoprotein classes.

18. An apparatus for the analysis of lipoprotein classes in a body fluid sample comprising:

a first device for detecting NMR reference data sets and characteristic reference parameters for each lipoprotein class as a function of different measuring conditions which are selected from the group consisting of different magnetic field gradients and varying temperatures,

a second device for detecting the NMR spectra of the body fluid sample under the same different measuring conditions as used in the first device, and

a third device for calculating an NMR spectra based on the NMR reference data, comparing the calculated NMR spectra to the NMR spectra of the body fluid sample detected in the second device by weighting with the characteristic reference parameters determined with the first device, and determining the concentrations and density and/or size distributions for each lipoprotein class in the body fluid sample based on the comparison.

19. The apparatus according to claim 18 , wherein

the first device comprises means for calculating the effects of the different measuring conditions on each lipoprotein class as a function of its density and/or size distribution,

the second device comprises means for detecting the actual effects of the different measuring conditions on each lipoprotein class in the body fluid sample as a function of its density and/or size distribution, and on each lipoprotein class,

the third device

contains means for fitting the calculated effects determined by the first device to the effects actually determined by the second device, by way of a weighting of the characteristic reference parameters by weighting factors and

means for calculating the density and/or size distribution of each lipoprotein class in the body fluid sample using the weighting factors.

20. The apparatus according to claim 18 , wherein

the first and/or second device comprises an NMR spectrometer,

the third device comprises a data processing facility.

21. A process for the determination of the concentrations of lipoprotein classes and subclasses in a body fluid sample comprising:

determining characteristic reference parameters of an NMR spectrum for each lipoprotein class and subclass to be analyzed, the characteristic reference parameters being determined using different and independent measuring conditions from those used in an apparatus to record measured NMR spectra of a body fluid sample, measuring the NMR spectra of the body fluid sample, calculating NMR reference spectra for each lipoprotein class and subclass using the characteristic reference parameters, and fitting the measured NMR spectra of a body fluid sample to the calculated NMR reference spectra by means of a weighting of the characteristic reference parameters using weighting factors in order to determine the concentrations of the lipoprotein classes and subclasses in the body fluid sample.

22. The process according to claim 21 , wherein

the characteristic reference parameters are selected from: chemical shift, NMR signal intensity and NMR signal form.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2015
From: NUMARES GMBH
To: NUMARES AG
Reel/Frame 036747/0254 →
CHANGE OF NAME Recorded Mar 15, 2013
From: LIPOFIT ANALYTIC GMBH
To: NUMARES GMBH
Reel/Frame 030018/0411 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2008
From: KREMER, WERNER; KALBITZER, HANS ROBERT; HUBER, FRITZ
To: LIPOFIT ANALYTIC GMBH
Reel/Frame 021537/0623 →
CONFIRMATORY LICENSE Recorded Sep 28, 2007
From: CORNELL UNIVERSITY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 019897/0599 →
Priority Claims (1)
DE 10 2004 026 903 · Jun 1, 2004 · national
Continuity (2)
Provisional Application 60576173 · Jun 1, 2004
Related Publication 20080038829A1 · Feb 14, 2008